76 completed, 6 terminated, 3 not yet recruiting, 3 withdrawn. 91 Phase 1, 21 Phase 2.
Follow Smoking Cessation: new trials by email Literature Review of Smoking Cessation trials Research Report on Smoking Cessation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Addressing Parental Tobacco Use in Somali Immigrant Families: Adapting an Evidence-Based Intervention in Primary Care CEASE+ - Smoking, Smoking Cessation | Phase 1 | Not yet recruiting | University of Minnesota | 50 | 2027-01-01 | 2026-02-27 |
| Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients Naltrexone Hydrochloride, Bupropion HCl Extended Release, Cognitive-Behavioral Therapy - Obesity, Smoking Cessation | Phase 1 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-10-01 | 2026-09-09 |
| A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy - Obesity, Smoking Cessation | Phase 1 / Phase 2 | Not yet recruiting | Medical University of South Carolina | 64 | 2026-09-01 | 2026-07-08 |
| A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g) - Thromboangiitis Obliterans (Buerger's Disease) | Phase 1 | Recruiting | Antidote Therapeutics, Inc | 15 | 2025-10-01 | 2025-10-15 |
| A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation lamivudine, rapamycin, Exercise Regimen - Smokers, Former Smokers | Phase 1 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 20 | 2025-08-12 | 2026-08-27 |
| Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia Naltrexone (Vivitrol), Bupropion - Smoking Cessation | Phase 1 | Terminated | The University of Texas Health Science Center, Houston | 2 | 2024-07-16 | 2025-09-16 |
| Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors EMI - Any Cancer Type | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2024-06-12 | 2026-04-02 |
| Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use Varenicline, Counseling, Guided Self-Change Booklets - Cigarette Smoking, E-Cigarette Use | Phase 1 | Completed | Yale University | 19 | 2024-04-01 | 2026-11-05 |
| Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers Cytisinicline - Smoking Cessation | Phase 1 | Completed | Achieve Life Sciences | 30 | 2023-08-08 | 2023-10-18 |
| Overcoming Nicotine Dependence to Enable Quitting Nicotine Replacement Therapy (NRT) Sampling, Practice Quitting (PQ) Counseling, Motivational Interviewing (MI) Counseling - Tobacco Use, Smoking Cessation | Phase 1 / Phase 2 | Recruiting | Rush University Medical Center | 780 | 2023-03-24 | 2026-09-09 |
| Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers Cytisinicline, Placebo, Moxifloxacin - Smoking Cessation | Phase 1 | Completed | Achieve Life Sciences | 27 | 2022-10-17 | 2023-05-18 |
| A First-in-Human Study of SBP-9330 in Healthy Subjects SBP-9330, Placebo - Smoking Cessation | Phase 1 | Completed | Camino Pharma, LLC | 90 | 2021-07-20 | 2024-04-16 |
| Study of EMB-001 as a Potential Smoking Cessation Treatment EMB-001 - Tobacco Use Disorder | Phase 1 / Phase 2 | Terminated | Embera NeuroTherapeutics, Inc. | 13 | 2021-06-10 | 2026-11-05 |
| A Multi Doses Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects BR9003 2mg, BR9003A 1mg - Smoking Cessation | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 27 | 2021-03-31 | 2021-08-18 |
| A Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects BR9003, BR9003A - Smoking Cessation | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 24 | 2021-03-25 | 2021-07-20 |
| STARS (Smoking Treatment And Remote Sampling) Study Varenicline 0.5 MG, Nicotine Replacement Therapy (NRT) - Smoking, Smoking Cessation | Phase 1 / Phase 2 | Completed | Medical University of South Carolina | 652 | 2021-02-08 | 2026-02-17 |
| Development of a mHealth Intervention for Ambivalent Smokers Control mHealth program, Experimental mHealth program, Nicotine patch - Tobacco Use Disorder, Smoking Cessation | Phase 1 | Completed | Kaiser Permanente | 57 | 2020-12-16 | 2023-01-23 |
| Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder Dextromethorphan - MDD, Treatment Resistant Depression | Phase 1 | Completed | Johns Hopkins University | 5 | 2020-03-15 | 2022-11-04 |
| Brain Imaging in Tobacco Smokers During a Quit Attempt [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide), Contingency Management - Tobacco Use Disorder, Tobacco Smoking | Phase 1 | Completed | Johns Hopkins University | 15 | 2019-12-16 | 2024-08-06 |
| A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers AZD4041, Placebo - Smoking Cessation | Phase 1 | Completed | AstraZeneca | 48 | 2019-10-03 | 2024-07-17 |
Showing 20 of 91. Sign in to see all of them.
Smoking (22) · Tobacco Use Disorder (17) · Cigarette Smoking (6) · Tobacco Use (5) · Harm Reduction (3) · Tobacco Use Cessation (3) · Obesity (2) · Tobacco Smoking (2) · Attention Deficit Disorder with Hyperactivity (1) · Behavior, Addictive (1) · Bipolar Disorder (1) · Depressive Disorder, Treatment-Resistant (1) · Glucose Intolerance (1) · Opioid-Related Disorders (1)
Behavior (91) · Health Behavior (91) · Mental Disorders (20) · Chemically-Induced Disorders (17) · Substance-Related Disorders (16) · Tobacco Use (7) · Smoking (6) · Pathological Conditions, Signs and Symptoms (5) · Tobacco Smoking (5) · Body Weight (4) · Signs and Symptoms (4) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3) · Overnutrition (3) · Mood Disorders (2)
Tobacco Use Cessation Devices (16) · Varenicline (7) · cytisine (7) · Cognitive Behavioral Therapy (6) · Nicotine (5) · Nicotine Replacement Therapy (4) · Tobacco, Smokeless (4) · Bupropion (3) · Counseling (3) · Naltrexone (3) · Sodium Chloride (3) · Motivational Interviewing (2) · 3-(1,4-diazabicyclo(3.2.2)nonan-4-yl)-6-fluorodibenzo(b,d)thiophene 5,5-dioxide (1) · Acceptance and Commitment Therapy (1) · Buspirone (1)
Pfizer (8) · Achieve Life Sciences (6) · McNeil AB (5) · Contract Research Organization el AB (4) · Pierre Fabre Medicament (4) · Yale University (4) · Fertin Pharma A/S (3) · Johns Hopkins University (3) · Medical University of South Carolina (3) · Boryung Pharmaceutical Co., Ltd (2) · Duke University (2) · GlaxoSmithKline (2) · Mayo Clinic (2) · Rutgers, The State University of New Jersey (2) · Selecta Biosciences, Inc. (2)
United States (54) · United Kingdom (6) · Sweden (5) · France (4) · Germany (4) · Belgium (3) · Portugal (3) · South Korea (3) · Canada (2) · South Africa (2) · Greece (1) · New Zealand (1) · Syria (1)
Elisabeth Kruse, PhD (5) · Erik Lunell, MD, PhD (3) · Marlene Fonseca, MD (3) · Annelize Koch, MD (2) · Caitlin E Smith, PhD (2) · Jonathan D Klein, MD, MPH (2) · Yolandi Swart, Dr. (2) · Alex Prokhorov, MD, PhD (1) · Alexander Lucardie, MD (1) · Amanda Mathew, PhD (1) · Andriani N Loukopoulou, PhD pending (1) · Annie Umbricht, M.D. (1) · Anupama Kumar (1)
PMID 18823182, PMID 19243716, PMID 23811612, PMID 24075893, PMID 25361769, PMID 26476459, PMID 30027479, PMID 30286396, PMID 30526213, PMID 33231550, PMID 33537575, PMID 33831213, PMID 34062053, PMID 35420700, PMID 37142273, PMID 37379059, PMID 41809575, PMID 42101840
2005 (2), 2017 (2), 2018 (1), 271201400069C-0-0-1 (1), 271201500019C-0-0-1 (1), K23DA025049 (1), K23DA064898 (1), K24DA023464 (1), K99CA271040 (1), P50CA196530 (1), P50DA009241 (1), R01CA081934 (1), R01CA195654 (1), R01DA021802 (1), R01DA026450 (1)